Pricing, Innovation & Presidential Politics: Today’s Shocking News
This article was originally published in RPM Report
Executive Summary
Over the last six months, drug pricing has been a headline issue in no small part thanks to the dynamics of Presidential politics. But latest news about former President Jimmy Carter is a reminder that there is another side of the issue.
You may also be interested in...
A New Idea To Solve The Turing Problem – If Anyone Notices
The Fair Pricing Coalition previewed its upcoming ‘first hundred days’ proposal for drug pricing reforms – one of many Washington policy documents that was prepared with a very different election result in mind. But one new idea in the report deserves serious attention because it would actually directly address the ‘repricing’ strategy that drove the headlines over the past year.
A New Idea To Solve The Turing Problem – If Anyone Notices
The Fair Pricing Coalition previewed its upcoming ‘first hundred days’ proposal for drug pricing reforms – one of many Washington policy documents that was prepared with a very different election result in mind. But one new idea in the report deserves serious attention because it would actually directly address the ‘repricing’ strategy that drove the headlines over the past year.
Clinton Vs. Trump: Three Scenarios For Biopharma
The presidential campaign is about to begin in earnest, and for biopharma companies, the biggest question is what the outcome will mean for the pricing climate in the US. It isn’t an easy question to answer.